SC Ad6 1
Alternative Names: SC-Ad6-1Latest Information Update: 28 Jul 2024
At a glance
- Originator Tetherex Pharmaceuticals
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In adults) in Australia (IM)
- 28 Jul 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In adults) in Australia (Intranasal)
- 06 Jul 2021 Mayo Clinic in-licenses SC Ad6 1 from Tetherex Pharmaceuticals